Emergent BioSolutions Takes Out Troubled Trubion For $97 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Known for its biodefense work, Emergent used cash from its anthrax vaccine contracts to scoop up a developer of antibody-like therapies for autoimmune and cancer indications.